pabolizumab
PreclinicalMonoclonal antibody
pabolizumab is one of 73 small molecule programs targeting Gastric Adenocarcinoma. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
72
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Cyramza
Eli LillyPhase 3
Tabrecta
NovartisPhase 3
Rozlytrek
RochePhase 3
Furmonertinib
AAllist Pharmaceuticals, Inc.
Phase 3
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for pabolizumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Preclinical[1]
- Company
- FFudan University